 TCF7L2 rs7903146 polymorphism and diabetic nephropathy association is not independent of type 2 diabetes -a study in a south Indian population and meta-analysis Związek między polimorfizmem rs7903146 genu TCF7L2 a nefropatią cukrzycową nie jest niezależny od cukrzycy typu 2 -badanie populacji Indii Południowych i metaanaliza 
Introduction
Diabetic nephropathy (DN) is a chronic microangiopathic complication of both type 1 (T1DM) and type 2 diabetes mellitus (T2DM) and is the primary cause of end stage renal disease (ESRD) [1] . Diabetes is characterised by hyperglycaemia resulting from the impairment of insulin secretion, insulin sensitivity, or both. Type 2
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diabetes is the most common form of diabetes, affecting 90% of all people with diabetes. The prevalence of type 2 diabetes continues to rise, with an increasing number of patients at risk of serious diabetes-related microvascular and macrovascular complications [2] . Both longitudinal and cross-sectional studies have demonstrated that type 2 diabetes is influenced by several behavioural as well as lifestyle factors [3] . Multiple lines of evidence indicate that type 2 diabetes is a highly inherited trait and different approaches such as candidate gene and linkage studies have been made to identify type 2 diabetes genes [4] [5] [6] . Genome wide association studies (GWAS) have paved the way for researchers to identify more genes that have a relatively low effect on type 2 diabetes susceptibility [7, 8] .
Transcription factor 7-like 2 is the key transcriptional factor regulating glucose metabolism through the Wnt signalling pathway. Wnt signalling has also been reported to be critical for the development of the pancreas and islets during embryonic growth. Furthermore, regulation of Wnt signalling's timing and stimulus is crucial for the development of the pancreas [9] . The gene TCF7L2 located on chromosome 10q25.3 which encodes the transcription factor-4 (TCF-4) has been identified as a major T2DM susceptibility gene. TCF7L2 rs7903146 SNP is associated with type 2 diabetes and may operate via impaired glucagon-like peptide 1 (GLP1) secretion, which is stimulated more by fat than by carbohydrate ingestion. Moreover, the association between TCF7L2 variants and T2DM is supported by several prospective mechanisms such as decreased β-cell mass, liver insulin resistance and altered chromatin state in 'T' allele carriers [10, 11] . However, causative links between polymorphisms in or near the TCF7L2 gene and overt type 2 diabetes are uncertain, because of the fact that the polymorphisms have not yet been proven to correlate with the risk for type 2 diabetes in prospective follow-up studies.
Thus, the objective of this study was to investigate the association of the TCF7L2 SNPs with SNP rs7903146 with well characterised DN. In particular, we investigated whether the association between TCF7L2 polymorphisms and DN is independent or dependent of diabetes. Further, we analysed the studies conducted so far on TCF7L2 gene rs7903146 in diverse populations of India, using meta-analysis to assess the possible heterogeneity in the allele frequency and the nature as well as the magnitude of its association with T2DM.
Material and methods

Subjects and methods
One hundred and twenty three unrelated individuals visiting outpatient clinics at Sri Ramachandra University Hospital, Chennai were diagnosed as type 2 diabetes according to the World Health Organisation criteria [12] . All participants underwent detailed clinical evaluation followed by biochemical investigations such as serum creatinine, fasting and postprandial blood glucose and 24-h urinary albumin excretion. Among them, 55 patients had overt nephropathy, as indicated by persistent urine albuminuria ( > 300 mg/L) in two consecutive measurements. Sixty eight individuals with normoalbuminuria indicated by urinary albumin excretion rate of < 20 µg/min even after ten years of diabetes were considered as controls. Eighty two age-and sex-matched healthy subjects were selected as controls. Individuals with hypertension, congestive heart defects and chronic renal disease were excluded from the study. This study was approved by the institutional ethics committee of Sri Ramachandra University. Informed written consent was obtained from all the study participants prior to the commencement of the study. Three ml of blood sample was collected from each participant, genomic DNA was isolated from lymphocytes by standard techniques, and we used a published protocol to genotype the TCF7L2 rs7903146 SNP [13] . Briefly, the rs7903146 was genotyped by amplifying 188 bp intron region of TCF7L2 gene by using forward primer 5′ ACA ATT AGA GAG CTA AGC ACT TTT TAG GTA 3′ and reverse primer 5′ GTG AAG TGC CCA AGC TTC TC 3′ followed by the digestion of PCR product with RsaI enzyme. The rs7903146 'T' allele was characterised by the presence of a 188 bp fragment, which was digested further to 159 and 29 bp fragments in rs7903146 'C' allele carriers.
A comprehensive search of the electronic databases: PubMed, Embase, and ISI Web of Science was done using the terms: 'transcription factor 7-like 2/TCF7L2', 'rs7903146' and 'type 2 diabetes mellitus/T2D/T2DM'. Papers pertaining to Indian populations with sufficient data retrieved up to April 2013 were considered for estimating an odds ratio (OR) and 95% confidence interval (CI) in the meta-analysis. All the studies included in the meta-analysis are listed in Table I . The data collected from the eligible studies included the study reference, total number of cases and controls, and numbers of genotypes in both cases and controls.
Statistical analysis
TCF7L2 rs7903146 allele frequencies of the present study and ten eligible case control studies were determined by direct gene counting. The genotype distribution of this SNP in all studies was evaluated for Hardy-Weinberg equilibrium by using a HWSIM program [14] . The strength of the association between TCF7L2 variant alleles and their interaction in causing diabetic nephropathy and T2DM was calculated using chi square analysis. The OR and corresponding 95% CI limits were also calculated. For TCF7L2 rs7903146, the meta-analysis examined the association between the carriers of the rare T allele and T2DM risk compared to that for CC genotype (CC vs. TC+TT). The pooled OR estimate of each study was calculated by the fixed-effects model [15] . The odds ratio and confidence interval was graphically presented as a forest plot. An estimate of potential publication bias was carried out by the funnel plot. Funnel plot asymmetry was assessed by the method of Egger's linear regression test [16] . The data was analysed using comprehensive meta-analysis software. For a worldwide comparison in a wider context, we have also extracted 20kb up and downstream SNPs around rs7903146 from the HapMap data (The International HapMap Consortium) [17] .
Results
Association study
The distribution of TCF7L2 rs7903146 genotypes among DN, diabetic control and normal controls is documented in Table II . The genotype frequency distribution in all three groups followed Hardy Weinberg equilibrium (Table II) . The frequency of 'T' allele was 31.9%, 36.8% and 26.2% in diabetic nephropathy, diabetic control, and normal control respectively. The results of association between different groups are also documented in Table II . The frequency of TT genotype was slightly higher in DN cases than the controls and increased the risk of nephropathy (p = 0.021, OR 4.30, 95% CI 1.00-21.44). The 'T' allele is associated with both diabetes (p = 0.049, OR 1.64, 95% CI 0.97-2.76) and diabetic nephropathy (p = 0.024, OR 1.81, 95% CI 1.04-3.13). The distribution of both allele and genotypes did not show significant differences between diabetes and diabetic nephropathy (Table II) .
Meta-analysis
Meta-analysis of 11 studies showed that the mutant allele is associated with T2DM in both fixed effect (P < 0.001, OR = 1.336, 95% CI = 1.255-1.422) and random effect (P = 0.004, OR = 1.254, 95% CI = 1.075-1.463) (Fig. 2) . Similar to the allelic meta-analysis, the pooled odds ratio for mutant genotypes (dominant model) showed a statistically significant association with T2DM adopting both fixed effect (P < 0.001, OR = 1.451, 95% 
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CI = 1.336-1.576) and random effect (P < 0.001, OR = 1.370, 95% CI = 1.150-1.832) (Fig. 2) . The heterogeneity test and sensitivity analysis showed a true heterogeneity between studies for 'T' allele in the allelic model (P heterogeneity < 0.001, χ 2 = 35.36, df = 10, I-squared = 74.5%) and dominant model (P heterogeneity = 0.003, χ 2 = 25.43, df = 10, I-squared = 64.6%). The comparison of heterogeneity between studies demonstrated that both allelic and dominant model show variations in study outcomes between studies.
The funnel plots generated using standard error and precision values for both allelic and dominant models using both fixed and random effect models are depicted in Figure 3 . The shape of the funnel plots was symmetrical, suggesting that there was no evidence for publication bias for rs7903146 polymorphism. The other measures used for assessing the publication bias in allelic and dominant models showed absence of publication bias (Table III) . The classic fail-safe 'N' value 
Figure 2. Forest plot of the fixed and random-effects meta-analysis of 11 studies of rs7903146 for T2DM (A. dominant model, B. allelic model). Point estimates, 95% confidence intervals (CI), and study weights are provided for each study
Rycina 2. Wykres typu forest plot efektów stałych i losowych w metaanalizie 11 badań polimorfizmu rs7903146 u osób z T2DM (A. model dominujący, B. model alleliczny). Dla wszystkich badań przedstawiono estymacje punktowe, 95% przedziały ufności i wagi
of 136 (P < 0.001, Z = 1.96) for allelic model and 130 (P < 0.001, Z = 1.96) for dominant model, indicated that 136 and 130 null studies (for allelic and dominant models respectively) would be required to convert the combined 'P' value as a non-significant P > 0.05. The Orwin's fail-safe 'N' value to bring observed Odds Ratio of 1.34 to 1.11 is 15 for allelic model, indicating a minimum of 15 null studies would be needed to bring the effect size to null. Similarly, Orwin's fail-safe 'N' value to bring the observed Odds Ratio of 1.45 to 1.11 is 23 for dominant model, indicating a minimum of 23 null studies would be needed to bring the effect size to null. Furthermore, the Duval and Tweedie's 'trim and fill' procedure also failed to show publication bias.
Discussion
Analysis of TCF7L2 rs7903146 in normal controls and diabetics with or without nephropathy demonstrated that the 'T' allele is associated with both diabetes and DN, but this association is not independent of T2DM.
The meta-analysis conducted using the 11 studies also showed a significant association between the mutant allele and T2DM in Indian populations. Furthermore, comparison on heterogeneity between studies confirmed that both the allelic and dominant models exhibited heterogeneity. No evidence or publication bias was observed. Although the role of TCF7L2 in the regulation of microvascular complications such as DN is not fully known, there have been several studies reporting the association of this gene with DN [18, 19] . Another study showed that the TCF7L2 gene was associated only with lower estimated glomerular filtration rate (eGFR) but not with albuminuria, indicating a shared genetic risk for T2DM and DN [20] . In contrast to this, no influence of this gene in the pathogenesis of diabetes-induced microvascular complications such as neuropathy, nephropathy and retinopathy has been observed [21] . The first report on a strong genetic association between variants of the TCF7L2 gene and risk of type 2 diabetes was found in Icelandic individuals, a Danish cohort, and a cohort of the US population [22] . The subsequent genome-wide association analysis on T2DM showed a strong signal for TCF7L2 in the French population [23] . This prompted inclusion of TCF7L2 gene variants in a large number of association studies in various populations world-wide [24] [25] [26] [27] [28] [29] . Furthermore, a number of meta-analyses supported this robust finding [30, 31] . The replication studies of TCF7L2 gene variants among Indian populations also showed a strong association of TCF7L2 with T2DM [32] [33] [34] [35] [36] . Investigations on transcriptional regulation by applying chromatin immunoprecipitation and sequencing techniques in a colorectal cancer cell line revealed overexpression of TCF7L2. This provided the first evidence for its central node for T2DM susceptibility [37] . Later, several studies using pancreatic cells and a rat insulin-producing cell line (Ins-1) have indicated a potential role of TCF7L2 in human T2DM [38] [39] [40] . A recent study demonstrated that the liver-specific TCF4 overexpression increases hepatic glucose production, indicating TCF7L2 directly activates metabolic genes [41] . To date, most studies with TCF7L2 have genotyped either the one or two most associated SNPs reported in the original study [22] , and ignored the remaining polymorphisms of the TCF7L2 gene. The rs7903146 also showed variations among the world populations with the highest 'T' allele frequency in HapMap populations of African (YRI, MKK, ASW and LWK) and European (CEU and TSI) followed by Mexican (MEX) ancestry and south Asian populations (GIH). East Asian populations (CHB, CHD and JPT) exhibited slightly fewer 'T' allele frequencies than the rest of the world populations (Table SI) .
Analysis of 20kb up and downstream SNPs around rs7903146 from the HapMap data demonstrated that the European (CEU and TSI) and Mexican (MEX) populations formed a single large LD block. Unlike in Caucasians, the African populations exhibited weak LD and formed two small LD blocks. In East Asian populations (CHB, CHD and JPT) and south Asian populations (GIH), the LD is fragmented (Fig.  S1) . Although the functional role of this intronic SNP (rs7903146) is still unknown, the variant risk allele is associated with impaired insulin secretion, reduction of total islet numbers, and quantitative as well as qualitative morphological changes in human islets [42] . Furthermore, carriers of risk variants at TCF7L2 are more likely to fail sulfonulyurea therapy than metformin and more likely to be on insulin therapy rather than diet alone. Thus, the screening of the entire gene leads to a complete understanding of the variants of exons and the surrounding region with a stronger effect on the risk of disease.
In conclusion, we suggest that TCF7L2 is a potent gene in not just causing T2DM, but also DN. This study could be extended to a larger number of diabetes-induced nephropathic individuals to gain more evidence. Thus it may prove to be a strong predictive classifier to provide an index of 'at risk' status, including probability estimates to T2DM likelihood and nephropathic complications thereafter. These studies can further aid in translational research, as categorising diabetic individuals based on their genetic makeup will help personalise medication and improve treatment options.
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